HeartSciences Discloses Fiscal 2026 Results, Fortitude Merger Progress, and FDA Submission Update
HSCS sits 33% above its 52-week low of $1.63.
Summary
HeartSciences filed an 8-K revealing fiscal 2026 results with minimal cash and equity, alongside fresh details on its Fortitude Mining merger—including robust Zcash mining metrics and a planned reverse stock split to preserve Nasdaq listing.
Key Events · Earnings and Guidance · HSCS
-
Fiscal 2026 Financials Reveal Precarious Position
As of April 30, 2026, HeartSciences reported no meaningful revenue, $1.7 million in cash, and stockholders' equity of just $0.2 million—figures that reinforce the going concern warning from its recent 10-K.
-
Fortitude Merger Details Quantified
Under the proxy statement, the merger will issue approximately 107.6 million shares of new Class V Common Stock to DCG, resulting in pro forma combined shareholders' equity of $70.0 million.
-
Fortitude's Operational Strength Highlighted
In the first half of 2026, Fortitude mined 72,696 ZEC—roughly 28% of global production—energized a new 60MW facility in Nebraska, and estimates run-rate Adjusted EBITDA above $50 million when Zcash prices exceed $500.
-
Reverse Stock Split Proposed to Maintain Nasdaq Listing
To meet Nasdaq listing requirements for the post-merger entity, a proposal seeks authorization for a reverse stock split at a ratio between 1-for-2 and 1-for-5.
Analysis · HSCS · Industrial Applications And Services
With no meaningful revenue, a cash balance of just $1.7 million, and stockholders' equity of $0.2 million, HeartSciences' fiscal 2026 results underscore the existential urgency of its pending all-stock merger with Fortitude Mining. The filing offers the first granular view of Fortitude's operations, including a commanding 28% share of Zcash production and a new 60MW facility poised to drive down mining costs. As the company confronts a Nasdaq listing threat and proposes a reverse stock split, this update frames the merger as a critical lifeline—giving shareholders exposure to a cash-flow-positive digital asset miner while the legacy ECG business awaits FDA clearance.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40.1% of the 1118 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSCS was trading at $2.17 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $1.63 to $3.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.